NAGE — Niagen Bioscience Cashflow Statement
0.000.00%
Last trade - 00:00- $350.75m
- $286.12m
- $129.42m
Annual cashflow statement for Niagen Bioscience, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -27.1 | -16.5 | -4.94 | 8.55 | 17.4 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 6.86 | 6.71 | 6.46 | -0.389 | 3.63 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -5.01 | -6.32 | 4.56 | 3.13 | -8.3 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | -24.2 | -15.1 | 7.12 | 12.1 | 13.5 |
| Capital Expenditures | -0.409 | -0.334 | -0.148 | -0.163 | -0.292 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 0 | — | 0.005 | 0.02 | 0 |
| Sale of Fixed Assets | |||||
| Change in Net Investments | |||||
| Cash from Investing Activities | -0.409 | -0.334 | -0.143 | -0.143 | -0.292 |
| Financing Cash Flow Items | -0.11 | -0.077 | -0.075 | -0.052 | -0.067 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 36.1 | 7.65 | -0.09 | 5.37 | 6.92 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 11.5 | -7.78 | 6.88 | 17.3 | 20.1 |